Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07768371 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07768371 · ClinicalTrials.gov record · last posted 2026-08-17

A 52-week Study of Remibrutinib in IgE-mediated Food Allergy

StatusNot Yet Recruiting
PhasePhase 3
Started2026-09-11
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin E (IgE)- mediated allergy in comparison to placebo.
Trial Details
NCT Number NCT07768371
Lead Sponsor Novartis Pharmaceuticals
Conditions IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
Enrollment 576 participants
Start Date 2026-09-11
Primary Completion 2029-03-30 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-17